knowledge -WSS

knowledge

author：focus 2025-09-02 22:02:03 - browse：328

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： A new House health package & hospitals’ new site

WSS

The 10 drugs up first for Medicare price negotiation

A new House health package & hospitals’ new site

AstraZeneca chief proposes a novel edit to the drug pricing bill

ALS advocates say criticism of new drugs misses bigger picture

Nevada Republican Sam Brown launching another Senate bid, teeing up marquee race

Why Novartis is changing the name of its research labs

hotspot

knowledge

focus

Walensky prepares to leave CDC — and Congress — behind

The 10 drugs up first for Medicare price negotiation

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

DIEP, the 'gold standard' of breast reconstruction, is under threat

Swim instructor mom warns parents not to buy blue swimsuits for kids

Medicare proposal to cover medical devices draws a mixed reaction

Stem cell treatment guidelines are released by FDA

Wildfire smoke exposes gaps in outdoor worker protections

Recent heat wave in the Mediterranean caused by climate change: Study

leisure time

Illumina names Agilent executive as new CEO

What American doctors can learn from their Israeli counterparts

Snackable artificial intelligence, expert AI, and the pharma industry

Presidential fundraising highlights so far: Trump brings in more than DeSantis

NIH nominee Bertagnolli will get October confirmation hearing

Weighted lottery helped low

hotspot

entertainment

leisure time

hotspot